Novartis expects to resume shipping drugs made at its Nebraska, US plant by the end of the year and is on track to fix other quality issues at Sandoz sites hits with 483s in 2011.
Outsourcing-Pharma.com presents a low-down of the latest chops and changes in the world of pharma and biopharma consultancy, including news from PM Group, MedCap and BioBridges.
US regulators approve cancer drugs faster than other medications and much faster than their European counterparts according to a new survey by the Tufts Center for the Study of Drug Development.
